Milestone Scientific Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $44.4M
- Price
- $0.5003
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.52%
- Volume
- 118.8K
About
Milestone Scientific Inc. designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. The company also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, it provides CompuFlo Epidural, a computer controlled anesthesia system for use in various medical applications. Further, the company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Livingston, New Jersey.
Quick stats
Shares outstanding88.7M
Computed float66.6M
Float / shares75.1%
Cash runway (months)182.3
Key info
SectorHealthcare
IndustryMedical - Instruments & Supplies
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000855683
AI Summary
AI-generated1/16
standardbullishearnings
Milestone Scientific Reports Financial Results for Second Quarter 2026
Milestone Scientific reported Q2 revenue of $2.8 million, up 22% year-over-year, while narrowing its net loss to $1.1 million from $1.5 million in the prior year period.
The medical segment drove growth with CompuFlo revenue increasing 230% YoY, supported by a new strategic distribution agreement with Red One Medical to supply the VA and Department of Defense.
Management reaffirmed its 2026 outlook for double-digit revenue growth to $9.8-$10.2 million and targets cash flow breakeven by early 2027.
Red flags
- Gross margin decreased to 67.2% from 69.6% due to tariffs and product mix
- Cash and cash equivalents of $2.1 million versus a $1.9 million net loss over the last six months indicates tight runway
- Q2 revenue benefited from two large international orders not expected to recur in Q3